The challenge
France requires every prescription medicine on the market to have an Exploitant — a licensed, locally established entity responsible for regulatory compliance. Building that presence in-house would have meant months of setup and a permanent overhead the company wasn't ready to commit to before proving out the market.
The Elliogen solution
1. Exploitant search & matchmaking
We identified and evaluated three vetted Exploitant candidates with direct experience in the client's therapeutic area, narrowing to the partner best suited to their launch timeline and compliance requirements.
2. Contract & compliance support
We negotiated a contract that clearly defined regulatory responsibilities and safety reporting lines between the client and their new Exploitant, closing the gaps that usually cause friction later in the relationship.
3. Seamless launch readiness
We integrated the Exploitant into the client's global systems and prepared their early access applications in parallel, so regulatory setup and commercial readiness moved on the same timeline instead of blocking each other.
The results
4 months
To market readiness
Zero
Regulatory issues at post-launch inspection
6 figures
Saved versus building a French subsidiary
Why it worked
The client's VP of Regulatory Affairs estimated the Exploitant route saved roughly twelve months and six figures compared with building French infrastructure independently — without compromising on regulatory confidence at launch.
Going through Elliogen to find our Exploitant meant we were inspection-ready from day one, without ever opening a French entity ourselves.